User:Bob K31416/BSA

"To observe any potential influence of BSA-based dosing on the pharmacokinetics and/or toxicity of paclitaxel, the BSA of potential patients was established to be ≤ 1.65 or ≥ 1.85 m2 (based on a mean BSA value with a ± SD percentage of 1.73 mg/m2 ± 5%)."

"Our initial assumption of an average BSA of 1.73 m2 came from a European Organization for Research and Treatment of Cancer (EORTC) database including 3,000 patients, both male and female, treated for sarcomas, lymphomas, and rectal cancers during the period from 1990 to 1998 (unpublished data). We agree with the author that more recent estimates for an adult, 21st century patient population may be somewhat higher. Fortunately, the ranges of observed BSA for the 2 tested BSA groups (between 1.462 and 1.539 m2 for the first group and between 1.875 and 2.097 m2 for the second; see Table 2 in our article) also conform to a mean BSA value of 1.8 m2 ± 5% standard deviation."

"We therefore retrospectively assessed the BSA of patients receiving chemotherapy treatment at three oncology centres in the UK between 1st January 2005 and 31st December 2005.

A total of 3613 patients receiving chemotherapy for head and neck, ovarian, lung, upper GI/pancreas, breast or colorectal cancers were included. The overall mean BSA was 1.79 m2 (95% CI 1.78–1.80) with a mean BSA for men of 1.91 m2 (1.90–1.92) and 1.71 m2 (1.70–1.72) for women."

There was an average BSA of 1.73 m2 for 3,000 cancer patients from 1990 to 1998 in a European Organisation for Research and Treatment of Cancer (EORTC) database.

During 2005 there was an average BSA of 1.79 m2 for 3,613 cancer patients in the UK. Among them the average BSA for men was 1.91 m2 and for women was 1.71 m2.